Late Stage Chronic Kidney Disease Therapeutics Market

Late Stage Chronic Kidney Disease Therapeutics Market Snapshot

The global demand for late stage chronic kidney disease therapeutics was valued at around US$ 4.7 Billion in 2019. However, with rising prevalence of chronic kidney disease across the globe, the overall late stage kidney disease therapeutics market is anticipated to surpass US$ 11.1 Billion in 2027 and forecast to grow at a prolific CAGR of around 11.6% throughout the forecast period (2022 –2032)

Chronic kidney disease (CKD) has been recognized as a leading public health problem worldwide due to its high morbidity and mortality rates. This fatal disease is usually caused by diabetes mellitus, hypertension, obesity, and aging.

Late stage chronic disease is an advanced stage of chronic renal disease where kidneys no longer function or work. This reduces the chances of survival and therefore requires proper treatment approaches including kidney transplant, dialysis and therapeutics. Among these, kidney transplant and dialysis are the only two effective treatments for CKD. However, dialysis is often costly and transplantation is limited by organ shortage. This has brought late stage chronic kidney disease therapeutics market into the spotlight.

Majority of the people with lower socioeconomic status and limited access to treatments are highly dependent on late stage chronic kidney disease therapeutics. These therapeutics can also be used in combination with dialysis.

Late stage chronic kidney disease therapeutics are drugs used for the treatment of late-stage chronic kidney disease induced hyperkalemia, hyperphosphatemia, hyperparathyroidism. Consumption of late stage chronic kidney disease therapeutics help to relieve the symptoms of CKD, delay late stage chronic kidney disease development, and thus enable patients to live longer lives without going through dialysis or transplantation.

Which Factors are Expected to Augment Growth of Late Stage Chronic Kidney Disease Therapeutics Market

Rising prevalence of chronic kidney disease (CKD) worldwide, rising awareness among people regarding the benefits of late stage chronic kidney disease therapeutics, introduction of favorable reimbursement policies for CKD treatment, higher diagnostic rates, and development of new effective therapeutics are some of the major factors expected to boost the growth of late stage chronic kidney disease therapeutics market during the forecast period.

Increasing incidence of chronic kidney disease is perhaps the major factor behind the robust expansion of late stage chronic disease therapeutics market. According to a report published in the Lancet, global prevalence of chronic kidney diseases reached around 700 million in 2017 and the numbers are expected to further surge during the upcoming years.

Similarly, the introduction of new advanced late stage kidney disease therapeutics along with poor access to renal replacement therapy and dialysis in developing countries is expected to favor market growth during the assessment period.

What are the Challenges Faced by the Late Stage Chronic Kidney Disease Therapeutics Industry

Despite its optimistic stance, the late stage chronic kidney disease therapeutics market is facing various obstacles that are restraining its growth to some extent. Some of these growth restraining factors are the delay in the diagnosis of CKD and increase in the number of kidney transplants.

Similarly, various side effects associated with late stage chronic kidney disease therapeutics is also limiting market growth.

Why is North America Considered a Prominent Market for Late Stage Chronic Kidney Disease Therapeutics

According to Future Market Insights, North America accounted for the largest share of the global late stage chronic kidney disease therapeutics market in 2021 and is projected to grow at the fastest CAGR over the forecast period. Growth in the market is attributable to the rising incidence of chronic kidney disease, availability of favorable reimbursement policies, and heavy presence of leading market players.

Demand for late stage chronic kidney disease therapeutics is particularly high across the United States due to surge in chronic kidney disease cases and easy availability of advanced therapeutics. According to the Centers for Disease Control and Prevention (CDC), around 37 million people in the United States are estimated to have chronic kidney disease.

Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

How Will Market Fare Across Asian Pacific

The Asia Pacific late stage chronic kidney disease therapeutics market is anticipated to grow at a considerable pace during the forecast period between 2022 and 2032, owing to the rising health awareness, growing prevalence of chronic kidney disease, and increasing government initiatives and investments to reduce the burden of chronic kidney disease.

According to the National Kidney Foundation, number of cases of kidney failure is expected to surge rapidly in developing countries, such as China and India, where the number of elderly people is increasing. This will generate lucrative growth prospects within the Asia Pacific late stage chronic kidney disease therapeutics market during the forecast period.

Market Competition

Some of the key participants present in the global late stage chronic kidney disease therapeutics market includes Amgen, Deltanoid, AbbVie, Sanofi, Ardelyx, AstraZeneca, Kyowa Hakko Kirin, Genzyme, Keryx, Spectrum, Mitsubishi Tanabe, OPKO Health, Relypsa, Shield Therapeutics, Shire,  Vifor and ZS Pharma among others.

These leading players are continuously investing in research and development to introduce more effective therapeutics. Besides this, they are partnering and collaborating with dialysis centers to increase their sales and gain a competitive edge in the market.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Sign-Up

Report Scope

Key Segments Profiled in the Late Stage Chronic Kidney Disease Therapeutics Industry Survey

By Product Type:

• Calcimimetics
• Sensipar (cinacalcet hydrochloride)
• Vitamin D Sterols
• Nutritional/Native Vitam:in D
• Vitamin D Receptor Agonists
• Phosphate Binders
• Calcium-Based Phosphate Binders
• Aluminum-Containing Phosphate Binders
• Magnesium-Containing Phosphate Binders
• Renvela/Renagel
• Fosrenol (lanthanum carbonate)
• Velphoro (sucroferric oxyhydroxide)
• Auryxia (ferric citrate)
• Potassium Binders
• Resins
• Veltassa (patiromer sorbitex calcium)

By Indication:

• Late Stage Chronic Kidney Disease Induced Hyperparathyroidism
• Late Stage Chronic Kidney Disease Induced Hyperphosphatemia
• Late Stage Chronic Kidney Disease Induced Hyperkalemia

By End Users:

• Hospital Pharmacy
• Retail Pharmacy
• Mail Order Pharmacy

By Region:

• North America
• Latin America
• Western Europe
• Eastern Europe
• APEJ
• Japan
• Middle East & Africa